"Avalon Globocare Corp. (OTCPK:AVCO) plans to acquire established companies, with revenue growth and defensible intellectual property within our target verticals, where they can leverage their global reach, capabilities and resources. They are initially targeting companies within the cell therapeutics, diagnostics and rehabilitation sectors, as they believe each of these markets are poised for explosive growth and leverage our core capabilities and expertise," David Jin, President and Chief Executive Officer of Avalon Globocare, said.